Dr. Mike Perry
and today. Thank everyone for thank you you, joining Caroline us
top million continued RECELL increase $X.X over exclude the record to deliver same which revenue quarter this to quarter. in $X.X line a revenues, strong We pleased commercial are year. to compared report growth we of revenue BARDA million And our last XX%
In XX%, in was were accounts, of new in Our larger the XXXX the normal the treated million in period commercial quarter, in improvement commercial year. to burn the access in ongoing activities the leading environment. base increase to meetings, XX, RECELL. million revenue centers with burn a overall $XX.X to With increase person cases of in we operating our half to achieved June $XX.X and corresponding an and resume year or able $X.X million, the ending penetration prior we greater in compared an
up care month the their to team XXX commercial first from each XXX in per cadence approximately over month, increased quarter. providers reach Our field training burn
selling ongoing use well, broaden the challenges began are to adoption, training addition, is has provider experiencing RECELL staffing An larger help size. broaden us case who further now with this increase allowed to particularly alleviate deeper summits our are to device constraints resonating are customers In field reach. penetration, and in to support, we and ease continuing that conduct with staffing accounts which to those ultimately I person coupled webinars of that designed our We order quarter, in mentioned. increased just
the to device shipped and new a have accounts. approximately We our quarter a release phase of
March. Turning the to our limited launch outpatient we initiated now market, in
an As patient we market portion expanded supporting our outpatient population become growth. our of to market will addressable new continued indications, a larger and important our increasingly
core are soft of inpatient, outpatient bulk comprise will the we burn expect procedures tissue While that treatment market. our
our cases working coverage. the to evaluation were such, care outpatient along during familiarize partner quarter. centers Japan, with Relative first completed to and pathways, in As and Japan coding training our COSMOTEC we with
body. mentioned last second I we XX-year reimbursement with in later to and like of story anticipate will regarding old in recent I'd a XX% his authorities year. up science Japanese in and the our wrap a which ongoing As call, which resulting this over are student highlight to degree media experiment discussions burns exploded, homeschooled pricing, third
degree to second customers. been at Joseph is while burn largest care saving one son's third which the boy the of Still have treatments addition the mother M. his Center burns, Burn States Hospital the and our Both his Doctors mother Georgia, sustained RECELL Augusta, and student, of and facility In life. largest The in United undergoing her of
the inspired during been far. encouraged son's by burn crisis, and family has thus uplifting both we're the the by mother this are the recovery We and which community,
soft in used our our The had both released had co-primary conventional standard statistically widely-meshed trial. pipeline Moving where achieving to just of reconstruction hypothesis We RECELL the indications. skin reconstruction vitiligo based with We a endpoint grafting. and hypothesis stable care of for donor non-inferiority on sparing the had endpoint sparing and control, the versus soft other conventional endpoints them grafting for made co-primary top-line data subject point. skin control trials. comparisons, One on solid superior healing. is study autographing superiority of of donor combination received progress now tissue RECELL thereby skin and tissue for treatment skin showed pairwise in each our
established statistical together between Nonetheless, pre-specified met. favorable of control, with healing safety record observed to and comparable benefit non a and point comparability While observed not was an statistically inferiority profile. RECELL was the in the risk donor sparing significant along healing RECELL
we planned tissue the As FDA approvals proceed such, in second soft as of with XXXX. for submission vitiligo both anticipated XXXX, half and later the with will in indications PMA
centers cases we As RECELL and we'll X to plans I with used mentioned the trauma previously, well, reconstruction, leverage tissue setting. are we approved and Level into once burn installed update initially and to X our existing the of to volume and infrastructure and XXX expect able centers another plan trauma high some From on future codes the there, our co-located centers, being base soft in our launch be you into grow our use to centers. burn XXX Level existing burn that currently Notably, system here reimbursement to burn trauma which calls. do as will centers
to excited address we've burn deploy are and efficiently We what care effectively tissue trauma to in learned opportunity. the soft
X.X and an which the as patient. million of month for sufferers calls. an There our attributed autoimmune vitiligo to the worldwide, supporting dermatologists' disorder skin clinical and/or our areas staff. million to of a I up and follow second physicians deep six on including vitiligo in we and the during in stated patients cell is are the disorder involves completion estimated use expect vitiligo current ups of premarket prior an XXXX. trial, patches, preparation Americans. To XXX With FDA of by recent pigmented spots appear top commercial their hands opportunity, line automated anticipated by that now to to are RECELL This primarily our previous underlying We of data or and by office RECELL submission end characterized we've as followed that the device. suspension Turning address white physician introduction with PMA to half of the time XXXX of best personnel vitiligo recognized in we make developing product approval support skin
differentiated to been and and of opportunity. since encouraged and AVITA treatment January by that attended over compelling vitiligo diligently are XX of the which the will marked working vitiligo very RECELL, market conferences entrants product record JAK recent this safety awareness on dermatology these believe this that the JAK year free one done sessions in and inhibitor in nature activities. treatment inhibitor, increase approval medically anticipate treatments. associated has We've We be as effective stimulated we this further vitiligo as limited well large interest the important. of features procedure has vitiligo multiple a of nine We will we topical of Overtime, disease options. a RECELL drive believe conferences commercially strong commercialization FDA's as at have year-over-year,
strategic remind growth these sessions. With that, received now numerous of in RECELL you like drivers. our Importantly, mentioned to I'd
momentum recent on education, We conversations. for healthcare we driving ahead, continued fall just in The in excited through focused our this conferences provider and maintaining burns. engagement are are in-person keenly
for of in second reconstruction submission Second, we those of XXXX, indications, plan and half both end markets anticipate by soft PMA tissue XXXX. and enter of supplements continue the to to we vitiligo the
our where on to Michael burn practice updating Michael? in bulk Lastly and in by are work progress soft we continued the to within objectives this center turning on RECELL encouraged look front now our later have pipeline year. setting pilot I With our financial performance the of of in advanced minds term key care the growth and establishing In details driving driver, in and indications. business anticipate RECELL milestones cases. training and performance achieved for longer our that, the summary, team's we over outpatient year it keeping commercial turn our forward to tissue this a our I'll executing you quarter continues, exciting in practitioners. future successfully several trauma I'm
